The alternative primary efficacy endpoint was reached. Avatrombopag, known under the brand name DOPTELET, is a thrombopoietin ...
A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...
The alternative primary efficacy endpoint was reached. Avatrombopag, known under the brand name DOPTELET, is a thrombopoietin receptor agonist (TPO-RA) that does not compete with thrombopoietin ...